PreDxion Bio is a cutting-edge biotechnology startup revolutionizing the healthcare industry with its slogan: "Pioneering accessible at-home diagnostics with a breakthrough saliva-based test for a range of respiratory diseases, from COVID-19 to the common cold." Founded in 2016, it focuses on providing affordable and user-friendly diagnostic solutions.
The company’s standout offering is its rapid, saliva-based test for detecting respiratory diseases such as COVID-19, flu, pneumonia, and the common cold. Utilizing a unique multiplexed localized surface plasmon resonance (LSPR) technology, PreDxion Bio aims to significantly advance at-home diagnostic testing.
The startup secured its last investment in a $6.25M Seed Round on 15 September 2020, with backing from notable investors like SignalFire and Hillsven Capital. This investment underscores confidence in its potential to transform healthcare diagnostics.